Abstract

Mycobacterium tuberculosis and other non-tuberculous mycobacteria are responsible for a variety of different infections affecting millions of patients worldwide. Their diagnosis is often problematic and delayed until late in the course of disease, requiring a high index of suspicion and the combined efforts of clinical and laboratory colleagues. Molecular methods, such as PCR platforms, are available, but expensive, and with limited sensitivity in the case of paucibacillary disease. Treatment of mycobacterial infections is also challenging, typically requiring months of multiple and combined antibiotics, with associated side effects and toxicities. The presence of innate and acquired drug resistance further complicates the picture, with dramatic cases without effective treatment options. Bacteriophages (viruses that infect bacteria) have been used for decades in Eastern Europe for the treatment of common bacterial infections, but there is limited clinical experience of their use in mycobacterial infections. More recently, bacteriophages’ clinical utility has been re-visited and their use has been successfully demonstrated both as diagnostic and treatment options. This review will focus specifically on how mycobacteriophages have been used recently in the diagnosis and treatment of different mycobacterial infections, as potential emerging technologies, and as an alternative treatment option.

Highlights

  • Mycobacterial infections are responsible for some of the most deadly and difficult to control infections in humans and animals

  • Opportunistic mycobacterial infections in people are caused by a range of non-tuberculous mycobacteria (NTM), including members of the M. avium complex (MAC) and M. abscessus complex (MAB)

  • The advantages of phages are numerous; only viable bacilli are detected whereas specificity is determined by the phage’s host range. They can be produced at a low cost, are easy to handle, and their rapid rate of infection can drastically reduce reporting times. Due to their several advantages, phages may fulfil the needs of modern TB diagnostics

Read more

Summary

Introduction

Mycobacterial infections are responsible for some of the most deadly and difficult to control infections in humans and animals. Other more recently identified and rarer NTM diseases include M. chimaera infections in cardiothoracic patients following exposure to contaminated heater-cooler units, unusual NTMs infections in immunocompromised hosts and BCGosis, a rare disseminated granulomatous disease, following intravesical Bacillus Calmette-Guérin (BCG) immunotherapy and in patients with predisposing genetic conditions such as the Mendelian susceptibility to mycobacterial diseases (MSMD) [2,3]. M. bovis is the primary cause of TB in cattle and other animals and causes 140,000 new cases and 11,400 deaths per year globally [1]. This review will focus on two separate but complementary topics: the use of bacteriophages for the diagnosis of mycobacterial infections and their use as alternative treatment options for challenging cases

Mycobacteriophages as Diagnostics
Bacteriophages as a Treatment Option for Mycobacterial Infections
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call